Invited Commentary
May 27, 2013

Exercise in Alzheimer Disease Comment on “Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): A Randomized Controlled Trial”

Author Affiliations

Author Affiliations: Department of Geriatrics, Soroka Hospital (Dr Clarfield); Medical School for International Health, Ben-Gurion University of the Negev (Drs Clarfield and Dwolatzky), and Department of Geriatrics and Memory Clinic, Mental Health Center (Dr Dwolatzky), Beersheva, Israel; and McGill University, Montreal, Quebec, Canada (Dr Clarfield).

JAMA Intern Med. 2013;173(10):901-902. doi:10.1001/jamainternmed.2013.1215

Alzheimer disease (AD), first described more than a century ago, continues to challenge our generation. If we compare the therapeutic progress that modern science has made in this condition with that achieved in treating bacterial infectious diseases, we are unfortunately still in the preantibiotic era with respect to AD. Despite a huge leap in our understanding of the basic science and pathogenesis of this devastating neurodegenerative disease and the many clinical trials of various drugs with disease-modifying potential,1 we have seen little real progress in achieving a cure.2 Alzheimer disease is a frightful malady: early on for the person with failing cognition and loss of self-esteem and function, and later for the family and caregivers faced with an increasing burden of care and a drain on resources.

First Page Preview View Large
First page PDF preview
First page PDF preview